Intellia Therapeutics (NTLA) Cash from Financing Activities (2015 - 2026)

Intellia Therapeutics (NTLA) has reported Cash from Financing Activities for 12 consecutive years, with $33.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Financing Activities changed N/A year-over-year to $33.6 million; the TTM figure through Mar 2026 stood at $165.1 million (up 31.25% YoY), while the FY2025 annual figure was $131.5 million, down 29.21% from the prior year.
• Cash from Financing Activities advanced to $33.6 million in Q1 2026 per NTLA's latest filing, from $2.0 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $505.8 million in Q4 2022 and bottomed at $2.0 million in Q4 2025.
• Historically, Cash from Financing Activities has averaged $66.5 million across 5 years, with a median of $28.8 million in 2022.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities surged 22082.59% — and 2024, when it slumped 97.82%.
• Intellia Therapeutics' Cash from Financing Activities stood at $505.8 million in 2022, then plunged by 78.95% to $106.5 million in 2023, then plunged by 97.82% to $2.3 million in 2024, then fell by 14.67% to $2.0 million in 2025, then jumped by 1597.98% to $33.6 million in 2026.
• Business Quant data shows NTLA's Cash from Financing Activities at $33.6 million in Q1 2026, $2.0 million in Q4 2025, and $114.9 million in Q3 2025.